4 March 2019 - Recordati Rare Diseases Canada today announced the approval of Cystadrops, the first cysteamine solution approved by Health Canada for the treatment of corneal cystine crystal deposits in patients with cystinosis, from two years of age.

Cystinosis is an ultra-rare genetic metabolic disease that causes cystine – an amino acid – to accumulate in the body’s organs.

Read Recordati press release